Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher

ProQR Therapeutics N.V. (NASDAQ:PRQR) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The consensus estimated revenue numbers rose, with their view now clearly much more bullish on the company's business prospects.

Following the upgrade, the current consensus from ProQR Therapeutics' six analysts is for revenues of €21m in 2024 which - if met - would reflect a sizeable 102% increase on its sales over the past 12 months. Before the latest update, the analysts were foreseeing €17m of revenue in 2024. The consensus has definitely become more optimistic, showing a very substantial lift in revenue forecasts.

View our latest analysis for ProQR Therapeutics

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the ProQR Therapeutics' past performance and to peers in the same industry. It's clear from the latest estimates that ProQR Therapeutics' rate of growth is expected to accelerate meaningfully, with the forecast 155% annualised revenue growth to the end of 2024 noticeably faster than its historical growth of 23% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 18% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect ProQR Therapeutics to grow faster than the wider industry.

The Bottom Line

The highlight for us was that analysts increased their revenue forecasts for ProQR Therapeutics this year. They're also forecasting more rapid revenue growth than the wider market. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at ProQR Therapeutics.

Looking for more information? At least one of ProQR Therapeutics' six analysts has provided estimates out to 2026, which can be seen for free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.